1. Hashimoto E, Taniai M, Tokushige K. Characteristics and
diagnosis of NAFLD/NASH. J Gastroenterol Hepatol.
2013;28:64-70.
2. Takahashi Y, Fukusato T. Histopathology of nonalcoholic
fatty liver disease/nonalcoholic steatohepatitis. World J
Gastroenterol. 2014;20(42):15539.
3. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ.
Modeling the epidemic of nonalcoholic fatty liver disease
demonstrates an exponential increase in burden of disease.
Hepatol. 2018;67(1):123-33.
4. Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D,
Ahmed A. Clinical epidemiology and disease burden of
nonalcoholic fatty liver disease. World J Gastroenterol.
2017;23(47):8263.
5. Bessone F, Razori MV, Roma MG. Molecular pathways of
nonalcoholic fatty liver disease development and
progression. Cellular and molecular life sciences: Cell Mol
Life Sci. 2018;76(1):99.
6. Samarasinghe SM, Hewage AS, Siriwardana RC,
Tennekoon KH, Niriella MA, De Silva S. Genetic and
metabolic aspects of non-alcoholic fatty liver disease
(NAFLD) pathogenicity. Egypt J Med Human Genet.
2023;24(1):53.
7. Szabo G, Csak T. Role of MicroRNAs in NAFLD/NASH.
Dig Dis Sci. 2016 May;61(5):1314-24.
8. Yousefi M, Hashemi M-S, Peymani M, Ghaedi K ,Irani S,
Etemadifar M. Elucidating the Role of a Shared lncRNAmiRNA-mRNA Network in Exacerbating Parkinson’s
Disease Symptoms in the Context of COVID-19 Infection.
Gene Expr. 2024;23(2):83-97.
9. Zailaie SA, Khoja BB, Siddiqui JJ, Mawardi MH, Heaphy
E, Aljagthmi A, Sergi CM. Investigating the Role of NonCoding RNA in Non-Alcoholic Fatty Liver Disease.
Noncoding RNA. 2024;10(1):10.
10. Du C, Shen L, Ma Z, Du J, Jin S. Bioinformatic analysis
of crosstalk between circRNA, miRNA, and target gene
network in NAFLD. Front Genet. 2021;12:671523.
11. Golchin ME, Chaleshtori SR, Golchin M, Shiasi A,
Amirsoleimani F, Dolatabadi NF. Circ-MYO9B modulates
metabolic pathways in nonalcoholic steatohepatitis via
miR-193b-5p. Mol Biol Rep. 2025;53 (1):42.
12. Zheng Q, Bao C, Guo W, Li S, Chen J, Chen B, et al.
Circular RNA profiling reveals an abundant circHIPK3
that regulates cell growth by sponging multiple miRNAs.
Nat Commun. 2016;7(1):11215.
13. Xu C, Liu S, Fu H, Li S, Tie Y, Zhu J, et al. MicroRNA193b regulates proliferation, migration and invasion in
human hepatocellular carcinoma cells. Eur J Cancer.
2010;46(15):2828-36.
14. Shen C, Li J, Zhang Q, Tao Y, Li R, Ma Z, et al. LncRNA
GASAL1 promotes hepatocellular carcinoma progression
by up-regulating USP10-stabilized PCNA. Exp Cell Res.
2022;415(1):112973 .
15. Pang X, Wan W, Wu X, Shen Y. The Novel Action of miR‐
193b‐3p/CDK1 Signaling in HCC Proliferation and
Migration: A Study Based on Bioinformatic Analysis and
Experimental Investigation. Int J Genom.
2022;2022(1):8755263.
16. Ye Y, Guo J, Xiao P, Ning J, Zhang R, Liu P, et al.
Macrophages-induced long noncoding RNA H19 upregulation triggers and activates the miR-193b/MAPK1
axis and promotes cell aggressiveness in hepatocellular
carcinoma. Cancer Lett. 2020;469:310-22.
17. Du J, Ji Y, Qiao L, Liu Y, Lin J. Cellular endo‐lysosomal
dysfunction in the pathogenesis of non‐alcoholic fatty liver
disease. Liver Int. 2020; 40 (2):271-80.
18. Seebacher F, Zeigerer A, Kory N, Krahmer N, editors.
Hepatic lipid droplet homeostasis and fatty liver disease.
Semin Cell Dev Biol; 2020:108:72-81.
19. Caballero-Díaz D, Bertran E, Peñuelas-Haro I, MorenoCàceres J, Malfettone A, López-Luque J, et al. Clathrin
switches transforming growth factor-β role to protumorigenic in liver cancer. J Hepatol. 2020;72(1):125-34 .
20. Naboulsi W, Bracht T, Megger DA, Reis H, Ahrens M,
Turewicz M, et al. Quantitative proteome analysis reveals
the correlation between endocytosis-associated proteins
and hepatocellular carcinoma dedifferentiation. Biochim
Biophys Acta. 2016;1864(11):1579-85.
21. Yin W, Nie Y, Chen L, Wang Q, Liu S ,He X, et al.
Deregulation of microRNA-193b affects the proliferation
of liver cancer via myeloid cell leukemia-1. Oncol Lett
2018;15(3):2781-8.
22 . Ahn S, Baek SE, Yu Y, Kim ES, Myung K, Kim YH, et al.
The role of AP2M1 in oncofetal characteristics: integrative
in silico, in vitro, and in vivo analyses using zebrafish
models. Eu J Med Res. 2025;31(1):15 .
23. Kaksonen M, Roux A. Mechanisms of clathrin-mediated
endocytosis. Na Rev Mol Cell Biol. 2018;19(5):313-26.
24. McMahon HT, Boucrot E. Molecular mechanism and
physiological functions of clathrin-mediated endocytosis.
Nat Rev Mol Cell Biol. 2011;12(8):517-33 .
25. Kirchhausen T, Owen D, Harrison SC. Molecular structure,
function, and dynamics of clathrin-mediated membrane
traffic. Cold Spring Harb Perspect Biol.
2014;6(5):a016725 .
26. Dutta D, Donaldson JG. Search for inhibitors of
endocytosis: Intended specificity and unintended
consequences. Cell Logist. 2012;2(4):203-8 .
27. Breher-Esch S, Sahini N, Trincone A, Wallstab C, Borlak
J. Genomics of lipid-laden human hepatocyte cultures
enables drug target screening for the treatment of nonalcoholic fatty liver disease. BMC Med Genomics.
2018;11(1):111.
28. Safaroghli-Azar A, Sanaei M-J, Pourbagheri-Sigaroodi A,
Bashash D. Phosphoinositide 3-kinase (PI3K) classes:
From cell signaling to endocytic recycling and autophagy.
Eur J Pharmacology. 2023;953:175827.
29. Mayor S, Parton RG, Donaldson JG. Clathrin-independent
pathways of endocytosis. Cold Spring Harb Perspect Biol.
2014;6(6):a016758 .
30. Azarnia Tehran D, López-Hernández T, Maritzen T.
Endocytic adaptor proteins in health and disease: lessons
from model organisms and human mutations. Cells.
2019;8(11):1345.
31. Motley A, Bright NA, Seaman MN, Robinson MS.
Clathrin-mediated endocytosis in AP-2–depleted cells.
The Journal of cell biology. 2003;162(5):909-18.
32. Boucrot E, Saffarian S, Zhang R, Kirchhausen T. Roles of
AP-2 in clathrin-mediated endocytosis. PloS one.
2010;5(5):e10597.
33. Hoxhaj G, Manning BD. The PI3K–AKT network at the
interface of oncogenic signalling and cancer metabolism.
Nat Rev Cancer. 2020;20(2):74-88.